Any current/future new fundraising through debt or equity?

Blue Jet Healthcare Limited indicated plans for fundraising related to a Rs. 1500 crore number mentioned in announcements. The exact details, including how much they intend to raise, have not been finalized or disclosed yet. Shiven Arora mentioned that more visibility on the fundraising plans would be shared in the immediate upcoming quarter. Although the decision to raise funds has been made, the company is not yet in a position to disclose specific details. No clear distinction was provided on whether the fundraising will be through debt, equity, or a combination.

Any current/future capex/capital investment/strategic investment?

Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad. Additional capacity being built at Mahad Unit-3, a continuous plant for KSM making, expected to go live in H2 FY'26. Multipurpose Plant (MPP) under construction in Mahad, highly automated with ~30 reactors, capacity expected by second half of FY'27; CAPEX for MPP revised upwards to ~Rs. 300 crores. State-of-the-art R&D center being built in Hyderabad at Rs. 40 crores, focusing on peptides, GLP-1 intermediates, biocatalysts. Acquisition of land in GIDC Dahej, Gujarat for further expansion for CMI and

Future growth expectations in sales/revenue/volumes?

Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 crore per quarter. Contrast media segment depressed in H1 FY'25 but rebounded in H2; new product validations including NCE molecules contributing to growth expected in FY'26 and FY'27 (e.g., iodinated intermediate expected to ramp up fully in FY'27). PI-API segment grew by 388% YoY, driven by advanced intermediates in cardiovascular therapy; order book fully served with new capacity at Ambernath

Future growth expectations in earnings/operating earnings/profits/EPS?

Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum. Management expects continued growth driven by ramp-up in pharma intermediates and API segments, with advanced intermediates and cardiovascular molecules scaling up further in FY'26. New product validations in contrast media and launch of iodinated intermediate expected to add growth from H1 FY'26, with full potential visible in FY'27. EBITDA margins improved to 37%; no forward guidance given, but operational leverage and cost discipline should further i

Current/ Expected Orderbook/ Pending Orders?

The current order book for pharma intermediates is fully served with new capacity added at Ambernath, resulting in a 388% jump compared to FY'24. Supplies for an NCE molecule started in Q4, with expected linear order book growth aligned with this molecule's growth. The iodinated intermediate is expected to launch in H1 FY'26, with full potential realization anticipated in FY'27. Discussions with customers provide good demand visibility; the Company bases volume supply on these forecasts, not on external speculations. Cardiovascular intermediate capacity utilization is about 60%-65%, in

IN US

Sale is live|00:00:00left today

Blue Jet Healthcare LtdQ1 FY25Pharmaceuticals & Biotechnology

Blue Jet Healthcare Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹525P/E: 25.4Market Cap: ₹7.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1

→Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 crore per quarter.
→Contrast media segment depressed in H1 FY'25 but rebounded in H2; new product validations including NCE molecules contributing to growth expected in FY'26 and FY'27 (e.g., iodinated intermediate expected to ramp up fully in FY'27).
→PI-API segment grew by 388% YoY, driven by advanced intermediates in cardiovascular therapy; order book fully served with new capacity at Ambernath.
→Europe and Latin America markets for cardiovascular molecules growing faster than in the US.
→Overall revenue grew 45% in FY'25; company aims to sustain growth momentum with strong customer demand, multi-year contracts, and capacity headroom.
→No forward guidance on exact numbers, but linear growth and high single-digit growth anticipated from key products.
→New capacities (Mahad Unit-3) expected online by H2 FY'26, supporting further ramp-up.

Margin guidance

Category 3

→Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum.
→Management expects continued growth driven by ramp-up in pharma intermediates and API segments, with advanced intermediates and cardiovascular molecules scaling up further in FY'26.
→New product validations in contrast media and launch of iodinated intermediate expected to add growth from H1 FY'26, with full potential visible in FY'27.
→EBITDA margins improved to 37%; no forward guidance given, but operational leverage and cost discipline should further improve margins.
→Capacity expansions at Ambernath, Mahad Unit-3 (backward integration), and new Dahej site to support future volume growth.
→EPS doubled in FY'25 to ₹17.59, suggesting strong earnings growth potential aligned with capacity additions and product ramp-ups.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Blue Jet Healthcare Limited indicated plans for fundraising related to a Rs. 1500 crore number mentioned in announcements.
→The exact details, including how much they intend to raise, have not been finalized or disclosed yet.
→Shiven Arora mentioned that more visibility on the fundraising plans would be shared in the immediate upcoming quarter.
→Although the decision to raise funds has been made, the company is not yet in a position to disclose specific details.
→No clear distinction was provided on whether the fundraising will be through debt, equity, or a combination.

Order book

Yes

→The current order book for pharma intermediates is fully served with new capacity added at Ambernath, resulting in a 388% jump compared to FY'24.
→Supplies for an NCE molecule started in Q4, with expected linear order book growth aligned with this molecule's growth.
→The iodinated intermediate is expected to launch in H1 FY'26, with full potential realization anticipated in FY'27.
→Discussions with customers provide good demand visibility; the Company bases volume supply on these forecasts, not on external speculations.
→Cardiovascular intermediate capacity utilization is about 60%-65%, indicating room for growth and readiness to capture demand upticks.
→Ongoing capacity expansion at Mahad (Unit-3) will enhance supply, aiming for validation and commercial production in H2 FY'26.
→Active discussions and contracts are ongoing with key customers (Esperion, Daiichi) for pharmaceutical products supply.

Capex plans

Yes

→Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad.
→Additional capacity being built at Mahad Unit-3, a continuous plant for KSM making, expected to go live in H2 FY'26.
→Multipurpose Plant (MPP) under construction in Mahad, highly automated with ~30 reactors, capacity expected by second half of FY'27; CAPEX for MPP revised upwards to ~Rs. 300 crores.
→State-of-the-art R&D center being built in Hyderabad at Rs. 40 crores, focusing on peptides, GLP-1 intermediates, biocatalysts.
→Acquisition of land in GIDC Dahej, Gujarat for further expansion for CMI and pharma intermediates; timelines not yet firm.
→Process excellence initiative at Unit-2 with Rs. 60 crores committed for solvent recovery units to reduce waste and improve recycling.
→Overall CAPEX strategy aligned with client lock-ins, demand visibility from new molecules, and supply chain resilience efforts.

How does Blue Jet Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Blue Jet Healthcare Ltd

Rev 1Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Blue Jet Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio